期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

儿童肺动脉高压靶向药物治疗 被引量：3

Targeted drug therapies for pediatric pulmonary hypertension
原文传递
导出
摘要 儿童肺动脉高压(PH)是以增高的肺动脉压力和肺血管阻力为特征的临床血流动力学综合征,预后不良,可导致心力衰竭和死亡。采用靶向药物可改善预后。根据美国食品药品管理局批准治疗PH的药物主要应用于以下3条分子通路之一:一氧化氮(NO)可溶性鸟苷酸(SGC)-环磷鸟苷(c GMP)通路,PGI2-环磷腺苷(c AMP)及内皮素-1(EF-1)通路。 Pulmonary hypertension （PH） in children is charac- terized by increased pulmonary artery pressure and pulmonary vascular resistance of clinical hemodynamic syndrome, and its prognosis is poor, which can lead to heart failure and death.The targeted drugs can improve the prognosis.According to the FDA approval, drugs are mainly used in one of the following three molecular pathways to treat PH：nitric oxide （NO） can be derived to guanosine monophosphate （SGC）- cyclic GMP （cGMP） pathway, PGI2-adenosine cyclophosphate （cAMP） pathway andendothelin 1 （EF-1） pathway.
作者 李渝芬 张旭
机构地区 广东省心血管病研究所心儿科广东省人民医院(广东省医学科学院)
出处 《中国实用儿科杂志》 CSCD 北大核心 2015年第6期416-421,共6页 Chinese Journal of Practical Pediatrics
关键词 儿童 肺动脉高压 靶向药物 children pulmonary hypertension targeted drugs
分类号 R72 [医药卫生—儿科]
  • 相关文献

参考文献28

  • 1Goldman AP, Delius RE, Deanfield JE, et al. Pharmacological control of pulmonary blood flow with inhaled nitric oxide after the fenestrated Fontan operation [J]. Circulation, 1996, 94 (9 Suppl) : 1144-1148.
  • 2Nagendran J, Archer SL, Soliman D, et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle and acute inhibition of phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle and acute inhibition of phosphodiesterase type5 improves con- tractility [ J ]. Circulation, 2007,116 (3) : 238-248.
  • 3Humpl T, Reyes JT, Holtby H, et al. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hyperten- sion:twelve-month clinical trial of a single-drug,open-label, pilot study[J]. Circulation. 2005,111 (24) : 3274-3280.
  • 4Schulze-Neick I, Penny D J, Rigby ML, et al. L-arginine and substance P reverse the pulmonary endothelial dysfunction caused by congenital heart surgery [J]. Circulation, 1999, 100 (7) :749-755.
  • 5Smith HA, Canter JA, Christian KG, et al. Nitric oxide precur- sors and congenital heart surgery : a randomized controlled trial of oral eitrulline [J]. J Thorac Cardiovasc Surg, 2006, 132 (1) : 58-65.
  • 6Grimminger F, Weimann G, Frey R, et al. First acute haemo- dynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension [J]. Eur Respir J, 2009, 33 (4) : 785-792.
  • 7Ghofrani HA, Hoeper MM, Halank M, et al. Riociguat for chron- lC thromhoemholie pulmonary hypertension and pulmonary arte- rial hypertension: a phase II study [J]. Eur Respir J, 2010, 36 (4) :792-799,.
  • 8Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for prima- ry pulmonary hypertension in children[J]. Circulation, 1999, 99(9) :1197-1208.
  • 9Yung D, Widlitz AC, Rosenzweig EB, et al. Outcomes in chil- dren with idiopathic pulmonary arterial hypertension [J ]. Circu- lation, 2004,110 (6) : 660-665.
  • 10Rosenzweig EB, Kerstein D, Barst R J, Long-term prostaeyclin for pulmonary hypertension with associated congenital heart defects [ J ]. Circulation, 1999,99 (14) : 1858-1865.

同被引文献58

  • 1Nold-Petry CA, Rudloff I,Baumer Y,et al. IL-32 promotes angiogen-esis[ J]. J Immunol,2014,192(2) :589-602. DOI: 10. 4049/jimmu-nol. 1202802.
  • 2Jiang Y,Nohe A, Bragdon B,et al. Trapping of BMP receptors indistinct membrane domains inhibits their function in pulmonary arte-rial hypertension [ J ]. Am J Physiol Lung Cell Mol Physiol,2011,301(2) : L218-227. DOI: http://dx. DOI. org/10. 1152/ajplung.00300.2010.
  • 3Zhao M,Austin ED,Hemnes AR,et al. An evidence-based knowl-edgebase of pulmonary arterial hypertension to identify genes andpathways relevant to pathogenesis[ J]. Mol Biosyst,2014,10(4):732-740. DOI: 0.1039/c3mb70496c.
  • 4Van Wijk B,Moorman AF, Van Den Hoff MJ. Role of bone mor-phogenetic proteins in cardiac differentiation [ J]. Cardiovasc Res,2007,74(2) :244-255. DOI: 10.1016/j. cardiores. 2006.11.022.
  • 5Kishigami S,Mishina Y. BMP signaling and early embryonic pat-terning [J]. Cytokine Growth Factor Rev, 2005,16 (3) : 265-278.DOI: 10.1016/j. cytogfr. 2005.04.002.
  • 6Miyazono K,Kamiya Y,Morikawa M. Bone morphogenetic proteinreceptors and signal transduction[ J]. J Biochem,2010,147 (1):35-51. DOI: 10.1093/jb/mvpl48.
  • 7Teichert-Kuliszewska K, Kutryk MJ, Kuliszewski MA, et al. Bonemorphogenetic protein receptor-2 signaling promotes pulmonary arte-rial endothelial cell survival : implications for loss-of-function muta-tions in the pathogenesis of pulmonary hypertension [ J ]. Circ Res,2006,98(2) :209-217.D01:10.1161/01.RES.0000200180.01710.e6.
  • 8Wei ZQ,Salmon RM,Upton PD,et al. Regulation of bone morpho-genetic protein 9(BMP9)by redox-dependent proteolysis[ J]. J BiolChem,2014,289 (45 ) : 31150-31159. DOI: 10. 1074/jbc. Ml 14.579771.
  • 9Lafyatis R. Transforming growth factor beta~at the centre of system-ic sclerosis[ J]. Nat Rev Rheumatol,2014,10(12) :706-719. DOI:10.1038/nrrheum. 2014.137.
  • 10Zhang YE. Non-Smad pathways in TGF-beta signaling [ J]. CellRes,2009,19(1) :128-139.DOI:10.1038/cr.2008.328.

引证文献3

二级引证文献17

中国实用儿科杂志
2015年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部